StockData
Insight Molecular Diagnostics Inc. logo

Insight Molecular Diagnostics Inc. (IMDX) stock

IMDXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 7/30
$1.78−0.08 (-4.30%)

Close on Nov 17, 2026Market cap $58.25MP/E –Yield –

Insight Molecular Diagnostics price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Insight Molecular Diagnostics's price to sales ratio was 46.7× on Nov 11, 2026, against 39.9× a year earlier. Over the last 5 years it ranged from 8.9× to 102.9×, with a median of 28.4×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 202646.7×−2.1
2025Dec 31, 202548.8×+3.9
2024Dec 31, 202444.9×+30.8
2023Dec 29, 202314.1×+5.2
2022Dec 30, 20228.9×−34.2
2021Dec 31, 202143.1×–

More Insight Molecular Diagnostics figures

See a number that looks wrong?